A5102767636- Retinal Diseases and Treatments
- Retinal and Optic Conditions
- Retinal Imaging and Analysis
- Glaucoma and retinal disorders
- Ocular Diseases and Behçet’s Syndrome
- Retinal and Macular Surgery
- Retinopathy of Prematurity Studies
- Intraocular Surgery and Lenses
- Retinal Development and Disorders
- Ocular Surface and Contact Lens
- Cerebral Venous Sinus Thrombosis
- Acne and Rosacea Treatments and Effects
- Ocular Infections and Treatments
- Ocular Oncology and Treatments
- Corneal surgery and disorders
- Ophthalmology and Eye Disorders
- Advanced Glycation End Products research
- Corneal Surgery and Treatments
- Neonatal Respiratory Health Research
- Vascular Malformations Diagnosis and Treatment
- Optical Coherence Tomography Applications
- Alzheimer's disease research and treatments
- Angiogenesis and VEGF in Cancer
- Connexins and lens biology
- Cell Adhesion Molecules Research
Asociacion Para Evitar la Ceguera en México Hospital Dr. Luis Sánchez Bulnes
2014-2024
University of Colorado Denver
2010-2021
Centro de Investigaciones en Optica
2020
University of Wisconsin–Madison
2016
University of Colorado Anschutz Medical Campus
2013-2016
University of Wisconsin System
2016
Wills Eye Hospital
2016
University of Kansas
2016
Wake Forest University
2016
Hospital General Dr. Manuel Gea Gonzalez
2016
In Brief Purpose: To evaluate ocular function and systemic development in premature infants treated with intravitreal bevacizumab injections for retinopathy of prematurity over a period 5 years. Methods: A prospective, interventional, noncomparative case study. The primary outcome measure was visual acuity. secondary outcomes were structural assessment, other functional measurements, developmental state. Results: Eighteen eyes 13 consecutive patients divided into 3 groups: Group 1, Stage 4...
To evaluate ocular outcome in premature infants treated with intravitreal ranibizumab injections for retinopathy of prematurity (ROP) over a period 3 years.An interventional case series. Premature high-risk prethreshold or threshold ROP plus disease received an off label monotherapy ranibizumab. The primary was treatment success defined as regression neovascularisation (NV) and absence recurrence. secondary outcomes were systemic adverse events visual acuity.Six eyes included the study All...
Increased retinal vasopermeability contributes to diabetic retinopathy, the leading cause of blindness in working-age adults. Despite clinical progress, effective therapy remains a major need. Vasoinhibins, family peptides derived from protein hormone prolactin (and inclusive 16-kDa fragment prolactin), antagonize proangiogenic effects VEGF, primary mediator vasopermeability. Here, we demonstrate what believe be novel function vasoinhibins as inhibitors increased associated with retinopathy....
OBJECTIVE Increased retinal vasopermeability (RVP) occurs early in diabetes and is crucial for the development of sight-threatening proliferative diabetic retinopathy (DR). The hormone prolactin (PRL) proteolytically processed to vasoinhibins, a family peptides that inhibit excessive RVP related DR. Here, we investigate circulating levels PRL association with DR men test whether increased PRL, by serving as source ocular can reduce pathological diabetes. RESEARCH DESIGN AND METHODS Serum was...
Purpose: A growing body of evidence points to complement dysregulation in diabetes. Early studies have indicated the presence components inside eye patients with diabetic retinopathy, but these data been confounded by leakage proteins from systemic circulation into vitreous cavity. Methods: We took samples plasma and without proliferative retinopathy (PDR) measured levels 16 as well albumin. employed a normalized ratio using local albumin control for vascular Results: Before normalizing, we...
To report acute postoperative, presumed sterile endophthalmitis following intravitreal injection of triamcinolone acetonide (IVTA).Retrospective, interventional, multicenter study patients with IVTA injection.A total 922 injections were performed. Eight eyes 8 identified. The incidence was 0.87% (95% confidence interval, 0.38% to 1.70%). Median time presentation 1.5 days (range, 1 7 days). presenting visual acuity 20/563 20/80 light perception). Initial treatment included vitreous tap and...
To evaluate the anatomical and functional outcomes of intravitreal bevacizumab (1.25 or 2.5 mg) in treatment inflammatory choroidal neovascularization at 24 months.We reviewed clinical records 22 consecutive patients (23 eyes) with secondary to chorioretinal disease this interventional retrospective multicenter case series. Sixteen eyes (63.6%) received a dose 1.25 mg bevacizumab, 7 (36.4%) bevacizumab.At baseline, mean best-corrected visual acuity was 0.68 logarithm minimum angle resolution...
To evaluate the safety and efficacy of lotilaner ophthalmic solution, 0.25% for treatment blepharitis due to Demodex infestation compared vehicle control.In this phase II, randomized, controlled, double-masked clinical trial, 60 eligible participants with were randomly assigned in a 1:1 ratio receive either topical (Tarsus Pharmaceuticals, Inc., Irvine, CA) (study group) or without (control bilaterally twice day 28 days. Participants followed at Days 7, 14, 28, 90. The parameters change...
This retrospective report describes our 20 months'experience using intravitreal injections of bevacizumab for the treatment several retinal diseases. We describe experience after 1765 in different proliferative retinopathies – retinopathy prematurity, choroidal neovascularization, diabetic retinopathy, among others. believe that findings reported this study move us closer to a better pathologies. However, further studies need be performed order determine safety and long-term efficacy either...
To investigate whether there are systemic effects of unilateral intravitreal administration bevacizumab on the untreated eye.Twenty-three consecutive patients were enrolled in this study. All had a clinical diagnosis bilateral diffuse diabetic macular edema with central retinal thickness greater than 275 microm by Optical Coherence Tomography. They treated 2.5 mg intravitreally worst eye based lines vision, number Early Treatment Diabetic Retinopathy Study letters, and thickness. The...
To maximize recovery after neurologic injury, physicians use therapeutic hypothermia of 90°F to 93°F (32.2-33.9°C). Temperatures below this are avoided because increased side effects. The extent which the retina is cooled during routine vitreous surgery unknown. This study seeks describe temperature changes and retinal surface surgery.In prospective 6 patients undergoing vitrectomy, a 23-gauge thermoprobe was used measure intraocular temperatures before, during, vitrectomy.Before mean...
BACKGROUND AND OBJECTIVE: To describe the 6-month safety and preliminary efficacy outcomes of use 24-Gy radiation with intravitreal ranibizumab for patients neovascular age-related macular degeneration (AMD). PATIENTS METHODS: A single treatment a non-invasive, externally delivered low-voltage x-ray irradiation at dose 24 Gy was administered in one session through three locations inferior pars plana consecutive series neo-vascular AMD (treatment naïve previously treated). Optical coherence...
<h3>Background/aims</h3> To report the long-term anatomical and functional outcomes of patients with centre-involved diabetic macular oedema (DME) treated intravitreal bevacizumab (IVB). <h3>Methods</h3> Retrospective case series. Patients diagnosed DME that were at least one injection 1.25 mg IVB had a minimum follow-up 60 months. underwent measurement best-corrected visual acuity (BCVA), ophthalmoscopy, optical coherence tomography fluorescein angiography baseline, 6-month, 12-month,...